C Aversa1, V Rossi2, E Geuna1, R Martinello1, A Milani1, S Redana3, G Valabrega1, M Aglietta1, F Montemurro4. 1. Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy; Department of Oncology, University of Torino Medical School, Italy. 2. Unit of Investigative Clinical Oncology (INCO), Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy. Electronic address: valentina.rossi@ircc.it. 3. Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy. 4. Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy; Department of Oncology, University of Torino Medical School, Italy; Unit of Investigative Clinical Oncology (INCO), Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy.
Abstract
BACKGROUND: Breast cancer (BC) subtypes have different survival and response to therapy. We studied predictors of central nervous system metastases (CNS-M) and outcome after CNS-M diagnosis according to tumor subtype. PATIENTS AND METHODS: 488 patients with diagnosis of metastatic BC were retrospectively evaluated. According to the combination of hormone receptors (HR) and HER2 status, tumors were grouped in: Luminal (Lum), Luminal/HER2+, pure HER2-positive (pHER2+) and triple negative (TN). Time to CNS progression, CNS-M free interval and Overall Survival (OS) after CNS-M occurrence were compared by the log-rank test. Cox-proportional hazard models were used to study predictor factors associated with CNS progression, including tumor subtype and all potentially clinical relevant variables. RESULTS: 115 patients (pts) developed CNS-M with a median time to CNS progression of 31 months. The rate of CNS-M by subtype was: Lum 14%, Lum/HER2+ 35%, pHER2+ 49%, TN 22% (p < 0.001). Compared with Lum tumors, Lum/HER2+ (HR 2.514, p < 0.001), pHER2+ (HR 6.799, p < 0.0001) and TN (HR = 3.179, p < 0.001) subtypes were at higher risk of CNS-M. Median OS in months after CNS-M was: Lum 7.4, Lum/HER2+ 19.2, pHER2+ 7, TN 4.9 (p < 0.002). Belonging to the Lum/HER2+ subtype (HR 0.48, p < 0.037) and having isolated CNS (HR 0.37, p < 0.004) predicted significantly reduced risk of death. CONCLUSIONS: After CNS-M, the Lum/HER2+ subtype appears associated with the longest OS. Prospective clinical trials would be required for evaluating the potential role of screening for asymptomatic CNS lesions and of more aggressive CNS-M treatment in Lum/HER2+ subtype.
BACKGROUND:Breast cancer (BC) subtypes have different survival and response to therapy. We studied predictors of central nervous system metastases (CNS-M) and outcome after CNS-M diagnosis according to tumor subtype. PATIENTS AND METHODS: 488 patients with diagnosis of metastatic BC were retrospectively evaluated. According to the combination of hormone receptors (HR) and HER2 status, tumors were grouped in: Luminal (Lum), Luminal/HER2+, pure HER2-positive (pHER2+) and triple negative (TN). Time to CNS progression, CNS-M free interval and Overall Survival (OS) after CNS-M occurrence were compared by the log-rank test. Cox-proportional hazard models were used to study predictor factors associated with CNS progression, including tumor subtype and all potentially clinical relevant variables. RESULTS: 115 patients (pts) developed CNS-M with a median time to CNS progression of 31 months. The rate of CNS-M by subtype was: Lum 14%, Lum/HER2+ 35%, pHER2+ 49%, TN 22% (p < 0.001). Compared with Lum tumors, Lum/HER2+ (HR 2.514, p < 0.001), pHER2+ (HR 6.799, p < 0.0001) and TN (HR = 3.179, p < 0.001) subtypes were at higher risk of CNS-M. Median OS in months after CNS-M was: Lum 7.4, Lum/HER2+ 19.2, pHER2+ 7, TN 4.9 (p < 0.002). Belonging to the Lum/HER2+ subtype (HR 0.48, p < 0.037) and having isolated CNS (HR 0.37, p < 0.004) predicted significantly reduced risk of death. CONCLUSIONS: After CNS-M, the Lum/HER2+ subtype appears associated with the longest OS. Prospective clinical trials would be required for evaluating the potential role of screening for asymptomatic CNS lesions and of more aggressive CNS-M treatment in Lum/HER2+ subtype.
Authors: Michael Offin; Daniel Feldman; Ai Ni; Mackenzie L Myers; W Victoria Lai; Elena Pentsova; Adrienne Boire; Mariza Daras; Emmet J Jordan; David B Solit; Maria E Arcila; David R Jones; James M Isbell; Kathryn Beal; Robert J Young; Charles M Rudin; Gregory J Riely; Alexander Drilon; Viviane Tabar; Lisa M DeAngelis; Helena A Yu; Mark G Kris; Bob T Li Journal: Cancer Date: 2019-08-30 Impact factor: 6.860
Authors: C Ryan Oliver; Megan A Altemus; Trisha M Westerhof; Hannah Cheriyan; Xu Cheng; Michelle Dziubinski; Zhifen Wu; Joel Yates; Aki Morikawa; Jason Heth; Maria G Castro; Brendan M Leung; Shuichi Takayama; Sofia D Merajver Journal: Lab Chip Date: 2019-03-27 Impact factor: 6.799
Authors: Shouyu Wang; Ke Liang; Qingsong Hu; Ping Li; Jian Song; Yuedong Yang; Jun Yao; Lingegowda Selanere Mangala; Chunlai Li; Wenhao Yang; Peter K Park; David H Hawke; Jianwei Zhou; Yan Zhou; Weiya Xia; Mien-Chie Hung; Jeffrey R Marks; Gary E Gallick; Gabriel Lopez-Berestein; Elsa R Flores; Anil K Sood; Suyun Huang; Dihua Yu; Liuqing Yang; Chunru Lin Journal: J Clin Invest Date: 2017-11-13 Impact factor: 14.808
Authors: Debu Tripathy; Sara M Tolaney; Andrew D Seidman; Carey K Anders; Nuhad Ibrahim; Hope S Rugo; Chris Twelves; Veronique Dieras; Volkmar Müller; Mary Tagliaferri; Alison L Hannah; Javier Cortés Journal: Future Oncol Date: 2019-05-10 Impact factor: 3.404
Authors: Minjee Kim; Sani H Kizilbash; Janice K Laramy; Gautham Gampa; Karen E Parrish; Jann N Sarkaria; William F Elmquist Journal: Pharm Res Date: 2018-07-12 Impact factor: 4.200
Authors: Anurag Saraf; Christopher S Grubb; Mark E Hwang; Cheng-Hung Tai; Cheng-Chia Wu; Ashish Jani; Matthew E Lapa; Jacquelyn I S Andrews; Sierra Vanderkelen; Steven R Isaacson; Adam M Sonabend; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Simon K Cheng; Eileen P Connolly; Tony J C Wang Journal: J Neurooncol Date: 2017-07-03 Impact factor: 4.130